The US Food and Drug Administration (FDA) has approved<unk>  for certain types of bladder and lung cancer: *Adults with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. *Adults with unresectable, Stage III non-small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. *In combination with etoposide and either carboplatin or cisplatin, as first-line treatment for adults with extensive-stage small cell lung cancer.
Durvalumab
Evolocumab
Olaratumab
Ustekinumab
Emapalumab
Alirocumab
Tralokinumab
Dupilumab